Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
Camillo Porta(University of Pavia), Mara De Amici(University of Pavia), Carlo Ganini, Chiara Paglino, Lucia Sacchi(University of Pavia), Ilaria Imarisio(University of Pavia), Vania Giunta(University Hospital Foundation), Silvana Quaglini(University of Pavia)
Cited by 78
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275